Accuray Incorporated (ARAY) is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in fourth-quarter fiscal 2024 performance and potential in the Precision Treatment Planning System (TPS) and Radiosurgery Market, is expected to contribute further. However, reimbursement uncertainties and stiff competition are concerning.This Zacks Rank #3 (Hold) company has lost 23% in the year-to-date period against 9.2% ...

Accuray Incorporated (ARAY) recently announced that Japan-based Gifu Prefectural General Medical Center became the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using its Radixact Radiation Delivery System and VitalHold (ARAY’s joint solution in partnership with C-Rad) package. The technology is expected to play a crucial role in the hospital's plan to expand patient access to high-precision radiation therapy treatments.Per Accuray, high-resolution cameras cont ...

MADISON, Wis., Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately. Accuray Senior Vice President and Chief Commercial Officer Sandeep Chalke will serve as the interim CEO during Ms. Winter's absence. To ensure that Mr. Chalke and the organization have the necessary support, the company has formed an ...

Accuray Incorporated (ARAY) has announced that its innovative CT-guided helical radiotherapy system, Accuray Helix, has received the CE Mark, signaling its readiness for deployment in global markets. Designed to meet the needs of emerging regions where access to advanced cancer care is limited, the Accuray Helix system offers a cost-effective solution for delivering high-performance, precise radiation treatments.Radiotherapy is an essential part of cancer treatment, effective for both localized and advanced ...

Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priorityDrives the next phase of company's strategic plan to expand its portfolio of helical radiation therapy delivery systemsMADISON, Wis., Aug. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high ...

baranozdemir Despite a well-received fiscal fourth quarter report that sent the shares up more than 50%, the reality is that Accuray (NASDAQ:ARAY) continues to struggle to show any real progress. This recently concluded fiscal year marked the third straight year of revenue in the $425M-$450M area, and the company has grown revenue by less than 2% a year over the past decade. While profitability has actually improved, the reality is that the shares have lost 25% of their value over the past five years (while ...

Accuray Incorporated (ARAY) and Halifax Health announced a breakthrough in cancer treatment at the Charles L. and Miki N. Grant Cancer Center for Hope in Port Orange, FL. The center's medical team became the first in the United States to treat cancer patients using Accuray’s Radixact System with VitalHold technology. This innovative system is designed to enhance the precision of radiation therapy by improving patient positioning and monitoring throughout the treatment process, offering a new standard of car ...

Accuray Incorporated (ARAY) reported fourth-quarter fiscal 2024 earnings per share (EPS) of 3 cents against the year-ago period’s reported loss of 3 cents per share. The bottom line missed the Zacks Consensus Estimate of 4 cents.Revenues in DetailAccuray registered quarterly revenues of $134.3 million, up 13.5% year over year. The figure beat the Zacks Consensus Estimate by 9.4%.The overall top-line growth was driven by higher product sales, partially offset by lower service revenues.At constant exchange ra ...

财务数据和关键指标变化 - 第四季度总收入为1.34亿美元,同比增长14%,创历史新高 [27][30] - 全年总收入为4.47亿美元,基本持平上一财年 [28][29] - 第四季度产品收入为8000万美元,同比增长28% [30] - 全年产品收入为2.34亿美元,基本持平上一财年 [30] - 第四季度服务收入为5500万美元,同比下降2% [31] - 全年服务收入为2.12亿美元,同比下降1% [31] - 第四季度毛利率为28.6%,上年同期为31.9% [32][33] - 全年毛利率为32%,上年同期为34.4% [34] - 第四季度营业利润为680万美元,上年同期为亏损50万美元 [36] - 全年营业利润为50万美元,上年同期为240万美元 [36] - 第四季度调整后EBITDA为1010万美元,上年同期为520万美元 [36][37] - 全年调整后EBITDA为1970万美元,上年同期为2390万美元 [36][37] 各条业务线数据和关键指标变化 - 第四季度CyberKnife系统订单同比增长31% [18] - Radixact系统占全年产品订单的70% [18] - 中国业务第四季度产品收入同比增长55% [11] - 日本业务第四季度产品收入同比增长1%,剔除汇率影响后增长13% [11] - 美洲地区第四季度产品收入同比下降50% [12] 各个市场数据和关键指标变化 - 国际市场全年收入同比增长10%,占总收入80% [29] - 中国全年收入同比增长27% [16] - 亚太地区(不含中国)全年收入同比增长14% [16] - EIMEA全年收入同比增长8.5% [16] - 日本全年收入同比下降11% [16] - 美洲地区全年收入同比下降26% [16] 公司战略和发展方向及行业竞争 - 公司进入中国二类市场,获得Tomo C产品的最终监管批准 [13][23] - 公司在印度推出Helix产品,并获得CE认证 [18][51] - 公司与GE Healthcare、RaySearch等公司建立新的战略合作伙伴关系 [21] - 公司在全球建立新的培训中心,提升服务能力 [17][59] - 公司看好中国和印度等新兴市场的长期发展潜力 [46][51] - 公司预计美国市场将在2025财年下半年开始逐步恢复 [24][70] 管理层对经营环境和未来前景的评论 - 管理层对公司第四季度和全年的整体表现感到满意 [8][15][25] - 管理层对公司在国际新兴市场的增长前景保持乐观 [8][16] - 管理层认为美国市场的短期挑战是暂时的,长期发展潜力仍然良好 [16][24] - 管理层表示将继续关注中国市场的反腐运动和刺激计划的影响 [24] - 管理层对公司未来3-5年的利润率扩张目标保持信心 [20][40] 其他重要信息 - 公司第四季度新增订单9500万美元,全年新增订单3.42亿美元 [31] - 公司期末订单总额为4.87亿美元,相当于2年以上的产品收入 [32] - 公司第四季度实现9.4百万美元的自由现金流 [38] - 公司2025财年收入指引为4.6-4.7亿美元,调整后EBITDA为2.75-2.95亿美元 [40] 问答环节重要的提问和回答 问题1 **Young Li 提问** 询问Tomo C在公司2025财年指引中的贡献情况,以及中国市场的反腐和刺激政策对公司的影响 [43][46] **Ali Pervaiz 回答** - Tomo C产品在2025财年指引中有一定贡献,预计从第二季度开始出货加速 - 公司将密切关注中国市场的反腐影响和刺激政策的推出时间,这些因素可能影响2025财年的安装时间 [46][47] 问题2 **Marie Thibault 提问** 询问公司在印度市场的计划,以及Cenos产品在美国FDA的审批进展 [51][52] **Suzanne Winter 回答** - 公司计划在今年内开始向印度市场发货Helix产品,看好印度市场的长期发展潜力 - Cenos产品的FDA审批进度有所延迟,计划在2025年ASTRO大会前全面推出 [51][52] 问题3 **Brooks O'Neil 提问** 询问公司在美国市场的竞争情况,以及服务业务的增长机会 [56][58] **Suzanne Winter 和 Ali Pervaiz 回答** - 公司在美国市场的订单增长快于整体市场,体现了产品创新的竞争优势 - 服务合同收入增长4.5%,反映了安装基数扩大和定价提升的效果,未来仍有较大增长空间 [58][59][61]

业绩总结 - FY24 年度营收为 446.6 百万美元，同比增长 0%[27] - FY24 年度毛订单为 342.1 百万美元，同比增长 10%[27] - FY24 年度产品收入为 234.2 百万美元，同比增长 0%[27] - FY24 年度服务收入为 212.4 百万美元，同比下降 1%[27] - FY25 年度营收预期为 460-470 百万美元，同比增长 3%-5%[34] - FY25 年度调整后 EBITDA 预期为 27.5-29.5 百万美元，同比增长 40%-50%[34] 新产品和新技术研发 - 在中国获得了 Accuray Precision® Treatment Planning System (TPS) 的批准，用于 Tomo® C 放疗系统，针对 B 类市场[19] - 在日本首次安装了 VitalHold 表面引导放疗系统 (SGRT) 在 Radixact® 系统上[20] - 在印度和其他潜力市场获得了 Accuray Helix 的 CE Mark，这是 Radixact® Treatment Delivery System 的一个配置[21] 市场扩张和并购 - Q4'FY24 公司历史上最高的季度收入，24%的系统出货量增长[18] 未来展望 - FY25 年度营收预期为 460-470 百万美元，同比增长 3%-5%[34] - FY25 年度调整后 EBITDA 预期为 27.5-29.5 百万美元，同比增长 40%-50%[34]